MXPA05004920A - Combinacion que comprende un inhibidor cdk y cisplatin. - Google Patents
Combinacion que comprende un inhibidor cdk y cisplatin.Info
- Publication number
- MXPA05004920A MXPA05004920A MXPA05004920A MXPA05004920A MXPA05004920A MX PA05004920 A MXPA05004920 A MX PA05004920A MX PA05004920 A MXPA05004920 A MX PA05004920A MX PA05004920 A MXPA05004920 A MX PA05004920A MX PA05004920 A MXPA05004920 A MX PA05004920A
- Authority
- MX
- Mexico
- Prior art keywords
- cisplatin
- cdk inhibitor
- combination
- relates
- cdk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un primer aspecto de la presente invencion se refiere a una combinacion que comprende un inhibidor CDK y cisplatin. Un segundo aspecto de la presente invencion se refiere a un producto farmaceutico que comprende un inhibidor CDK y cisplatin en la forma de una preparacion combinada para uso en forma simultanea, en secuencias o por separado en terapia. Un tercer aspecto de la presente invencion, se refiere a un metodo para tratar un padecimiento proliferativo, en donde el metodo comprende administrar a un sujeto en forma simultanea, en secuencias o por separado un inhibidor CDK y cisplatin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0225874A GB0225874D0 (en) | 2002-11-06 | 2002-11-06 | Combination |
| GB0300293A GB0300293D0 (en) | 2003-01-07 | 2003-01-07 | Combination |
| PCT/GB2003/004773 WO2004041267A1 (en) | 2002-11-06 | 2003-11-05 | Combination comprising a cdk inhibitor and cisplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05004920A true MXPA05004920A (es) | 2005-08-18 |
Family
ID=32313984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05004920A MXPA05004920A (es) | 2002-11-06 | 2003-11-05 | Combinacion que comprende un inhibidor cdk y cisplatin. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050276866A1 (es) |
| EP (1) | EP1558239A1 (es) |
| JP (1) | JP2006508185A (es) |
| AU (1) | AU2003276463A1 (es) |
| BR (1) | BR0316021A (es) |
| CA (1) | CA2502969A1 (es) |
| MX (1) | MXPA05004920A (es) |
| WO (1) | WO2004041267A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| ATE418333T1 (de) * | 2002-11-06 | 2009-01-15 | Cyclacel Ltd | Kombination aus docetaxel und einem cdk-hemmer |
| US20060136741A1 (en) * | 2004-12-16 | 2006-06-22 | Saflink Corporation | Two factor token identification |
| JP2012509859A (ja) * | 2008-11-24 | 2012-04-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 中皮腫の治療のためのｃｄｋ阻害物質 |
| JP2015510910A (ja) * | 2012-03-21 | 2015-04-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 特定の腫瘍の処置のための、（ｒｓ）−ｓ−シクロプロピル−ｓ−（４−｛［４−｛［（１ｒ，２ｒ）−２−ヒドロキシ−１−メチルプロピル］オキシ｝−５−（トリフルオロメチル）ピリミジン−２−イル］アミノ｝フェニル）スルホキシミドの使用 |
| JP6286421B2 (ja) | 2012-05-15 | 2018-02-28 | サイクラセル リミテッド | サパシタビン及びセリシクリブの投与レジメン |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| AU2002228849A1 (en) * | 2000-12-08 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
-
2003
- 2003-11-05 MX MXPA05004920A patent/MXPA05004920A/es not_active Application Discontinuation
- 2003-11-05 JP JP2005502133A patent/JP2006508185A/ja active Pending
- 2003-11-05 BR BR0316021-1A patent/BR0316021A/pt not_active Application Discontinuation
- 2003-11-05 CA CA002502969A patent/CA2502969A1/en not_active Abandoned
- 2003-11-05 EP EP03810525A patent/EP1558239A1/en not_active Withdrawn
- 2003-11-05 AU AU2003276463A patent/AU2003276463A1/en not_active Abandoned
- 2003-11-05 WO PCT/GB2003/004773 patent/WO2004041267A1/en not_active Application Discontinuation
-
2005
- 2005-05-03 US US11/121,753 patent/US20050276866A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0316021A (pt) | 2005-09-27 |
| WO2004041267A1 (en) | 2004-05-21 |
| EP1558239A1 (en) | 2005-08-03 |
| AU2003276463A1 (en) | 2004-06-07 |
| JP2006508185A (ja) | 2006-03-09 |
| CA2502969A1 (en) | 2004-05-21 |
| US20050276866A1 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05004919A (es) | Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina. | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
| WO2005000211A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
| TW200612922A (en) | Inhibitors of hsp90 | |
| UA86570C2 (ru) | Способ лечения некротизирующего энтероколита | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| GB0328180D0 (en) | Combination | |
| TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
| AU2003205768A1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| MXPA05004920A (es) | Combinacion que comprende un inhibidor cdk y cisplatin. | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| MXPA05004917A (es) | Combinacion que comprende docetaxel y un inhibidor cdk. | |
| MXPA04009012A (es) | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. | |
| WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| MXPA04009396A (es) | Combinacion que comprende un inhibidor cdk y doxorubicina. | |
| BR0316029A (pt) | Combinação | |
| WO2007054725A3 (en) | Combination of a cdk-inhibitor and a hdac-inhibitor | |
| TW200603792A (en) | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors | |
| MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |